ClinicalTrials.gg
CompletedNCT04709289Updated Jan 14, 2021

Adverse Effects of ALA-PDT for the Treatment of Moderate to Severe Acne Vulgaris: a Prospective Study

An interventional study of Aminolevulinic acid, photodynamic therapy in Acne Vulgaris, sponsored by Shanghai Dermatology Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-14.

Sponsored by Shanghai Dermatology Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2020, registered Jan 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Acne Vulgaris with a site in China — 8 open to participants now, 10 under way, 2 of them phase 3. Acne Vulgaris · China.

Enrollment
25th of 33
40 · median 100
Started
2020
with 2 others
No phase
14 of 35
3 open now
Registered
14th of 35
by date
Lead sponsor
4 of 35
Shanghai Dermatology Hospital

Among the 35 studies in Acne Vulgaris with a site in China, this one is the 25th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2020, is one of 14 with no phase, and was the 14th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

8 of the 35 studies in Acne Vulgaris with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Acne Vulgaris with a site in China, or all of them as a file.
02

Study summary

To understand, prevent and treat the adverse reactions more comprehensively, we sought to systemically document the adverse effects of ALA-PDT for moderate to severe acne vulgaris.

Read the detailed description

To understand, prevent and treat the adverse reactions more comprehensively, we sought to systemically document the adverse effects of ALA-PDT for moderate to severe acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Patients diagnosed with moderate to severe acne and graded grade III-IV according to Investigator's Global Assessment (IGA) ;
  • (2) Patients unsuitable for drug treatment owing to various reasons and who voluntarily participated and signed following information about other alternatives;
  • (3) Patients who read the instructions and were willing to follow the program requirements.

Exclusion criteria

Exclusion Criteria:

  • (1) Patients who had a history of photosensitive diseases;
  • (2) Patients who had Modified-PDT;
  • (3) Patients who had oral isotretinoin in the past 3 months, used oral or antibiotics and underwent local or facial surgery in the past 4 weeks;
  • (4) Female patients who were pregnant or lactating.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Conventional Photodynamic Therapy(C-PDT) group

    The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 140 J/cm2) after applying 5% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once every two weeks for 3 times.

    Other: Aminolevulinic acid, photodynamic therapy

Interventions

  • OtherAminolevulinic acid, photodynamic therapy

    Aminolevulinic acid, photodynamic therapy

06

What researchers measure

Primary outcomes

  1. The clearance rate of lesions

    The change rate in lesion clearance of acne vulgaris at 7 days after treatment will be measured as the primary outcome

    Time frame: 1 week after treatment

Secondary outcomes

  1. Assessment of adverse effects

    the incidence, severity, occurrence and duration time of erythema, pain, burning skin, itching, pustule, exudation, edema, blister, dry skin, crust and hyperpigmentation of last treatment, as well as lesion photos were detailed asked and recorded during the clinical encounter, up to 7 days after treatment.

    Time frame: up to 7 days after treatment.

07

Study locations

1 site
  • Lei Shi
    Shanghai, Shanghai 200443, China
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Jan 2020, 0 months.

Of 59 non-industry interventional studies with no phase under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 17. This study's 0 months is below that.

Counting every sponsor, half of 122 studies reached it within 9 months; a quarter within 4 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2021
First posted
Jan 14, 2021
StartActual
Jan 1, 2020
Primary completionActual
Jan 1, 2020
CompletionActual
Feb 28, 2020
Last update
Jan 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04709289
Lead sponsor
Shanghai Dermatology Hospital
Responsible party
Xiuli Wang (Director, Clinical Professor, Shanghai Dermatology Hospital) — Principal investigator
First posted
Jan 14, 2021
Start date
Jan 1, 2020
Primary completion
Jan 1, 2020
Completion
Feb 28, 2020
Last update
Jan 14, 2021

Study contacts

Xiuli Wang, MD PhD
study director · Shanghai Skin Disease Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion